Activity of paraoxonase 1 (PON1) and its relationship to markers of lipoprotein oxidation in healthy Slovaks

Acta Biochimica Polonica

Volumn 53, Issue 4, 2006, Pages 783-787

  Sumegová, Katarína ^a   Blažíček, Pavel ^b   Waczulíková, Iveta ^a   Žitňanová, Ingrid ^a   Ďuračková, Zdeňka ^a  

^a Physics and Informatics   (Slovakia)

^b Hospital of Ministry of Defence   (Slovakia)

Author keywords

Atherosclerosis; HDL; ox LDL; Paraoxonase 1

Indexed keywords

BOS TAURUS;

EID: 33846135726     PISSN: 0001527X     EISSN: 1734154X     Source Type: Journal    
DOI: 10.18388/abp.2006_3307     Document Type: Article

References (21)

1. Aviram M, Rosenblat M, Bisgaier ChL, Newton RS, Primo-Parmo SL, La Du BN (1998) Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role of paraoxonase. J Clin Invest 101: 1581-1590.
2. Beltowski J, Wójcicka G, Marciniak A (2002) Species- and substrate-specific stimulation of human plasma paraoxonase 1 (PON1) activity by high chloride concentration. Acta Biochim Polon 49: 927-936.
3. El-Saadani M, Esterbauer H, El-Sayed M, Goher M, Nassar AY, Jürgens G (1989) A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J Lipid Res 30: 627-630.
4. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18: 449-502.
5. Gan KN, Smolen A, Eckerson HW, La Du BN (1991) Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 19: 100-106.
6. Gouédard C, Koum-Besson N, Barouki R, Morel Y (2003) Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol Pharmacol 63: 945-956.
7. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D (1998) Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 98: 1487-1494.
8. Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R, Collen D, Muls E, Van de Werf F (2001) Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 21: 844-848.
9. Hulthe J, Fagerberg B (2002) Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR study). Arterioscler Thromb Vasc Biol 22: 1162-1167.
10. Kondo A, Muranaka Y, Ohta I, Notsu K, Manabe M, Kotani K, Saito K, Maekawa M, Kanno T (2001) Relationship between triglyceride concentrations and LDL size evaluated by malondialdehyde-modified LDL. Clin Chem 47: 893-900.
11. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M, Durrington PN (1991) Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 86: 193-199.
12. Mackness B, Durrington PN, Boulton AJM, Hine D, Mackness MI (2002) Serum paraoxonase activity in patients with type I diabetes compared to healthy controls. Eur J Clin Invest 32: 259-264.
13. Mertens A, Holvoet P (2001) Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J 15: 2073-2084.
14. Parthasarathy S, Santanam N, Ramachandran S, Meilhac O (2000) Potential role of oxidized lipids and lipoproteins in antioxidant defense. Free Radic Res 33: 197-215.
15. Sampson MJ, Braschi S, Willis G, Astley SB (2005) Paraoxonase-1 (PON-1) genotype and activity and in vivo oxidized plasma low-density lipoprotein in type II diabetes. Clin Sci 109: 189-197.
16. Sigurdardottir V, Fagerberg B, Hulthe J (2002) Circulating oxidized low-density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-years-old men (AIR study). J Intern Med 252: 440-447.
17. Teiber JF, Draganov DI, La Du BN (2004) Purified human serum PON1 does not protect LDL against oxidation in the in vitro assays initiated with copper or AAPH. J Lipid Res 45: 2260-2268.
18. Tomás M, Sentí M, García-Faria F, Vila J, Torrents A, Covas M, Marrugat J (2000) Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 20: 2113-2119.
19. Topçuoǧlu A, Uzun H, Aydin S, Kahraman N, Vehid S, Zeybek G, Topçuoǧlu D (2005) The effect of hormone replacement therapy on oxidized low density lipoprotein levels and paraxonase activity in postmenopausal women. Tohoku J Exp Med 205: 79-86.
20. Toshima S, Hasegawa A, Kurabayashi M, Itabe H, Takano T, Sugano J, Shimamura K, Kimura J, Michishita J, Suzuki T, Nagai R (2000) Circulation oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 20: 2243-2247.
21. Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D (1989) Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 84: 1086-1095.